CD274 and hepatocellular carcinoma: The IMbrave150 trial, a global phase 3 clinical trial, showed that combination therapy of atezolizumab plus bevacizumab (Atez/Bev), in which monoclonal antibodies bind to programmed cell death 1-ligand 1 (PD-L1) and antivascular endothelial growth factor (VEGF)-A, is the recommended first-line treatment for patients with u-HCC [8].